Top Page
Archer Materials
(Sydney:AXE)
Archer Materials (AXE) vs. iShares MSCI Australia ETF (EWA)
Archer Materials Business Overview & Revenue Model
Archer Materials Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 845.89K | 2.06M | 2.14M | 1.50M | 973.00K | 467.66K |
| Gross Profit | 795.39K | 2.06M | 2.14M | -53.74K | 922.59K | 435.36K |
| EBITDA | -7.74M | -6.94M | -5.11M | -8.66M | -14.97M | -3.24M |
| Net Income | -5.55M | -6.97M | -4.80M | -9.05M | -14.12M | -7.84M |
Balance Sheet | ||||||
| Total Assets | 14.87M | 17.47M | 22.89M | 27.21M | 30.17M | 19.69M |
| Cash, Cash Equivalents and Short-Term Investments | 10.32M | 13.82M | 18.78M | 24.19M | 28.17M | 8.93M |
| Total Debt | 6.90K | 14.97K | 109.31K | 9.10K | 19.75K | 30.09K |
| Total Liabilities | 909.76K | 752.16K | 1.09M | 1.21M | 746.23K | 732.71K |
| Stockholders Equity | 13.96M | 16.72M | 21.80M | 26.00M | 29.42M | 18.96M |
Cash Flow | ||||||
| Free Cash Flow | -6.47M | -4.19M | -4.99M | -3.21M | -4.44M | -2.32M |
| Operating Cash Flow | -6.45M | -4.19M | -4.79M | -3.03M | -4.30M | -2.22M |
| Investing Cash Flow | 9.38M | 4.11M | 6.98M | 2.31M | -94.83K | -262.25K |
| Financing Cash Flow | -18.73K | -96.30K | -115.82K | 64.90K | 24.62M | 606.22K |
Archer Materials Technical Analysis
Archer Materials Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$56.89M | -10.26 | 7.40% | 5.97% | -18.05% | -51.45% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | AU$1.04B | -8.87 | -57.61% | ― | 333.23% | 10.83% | |
49 Neutral | AU$86.65M | -7.24 | -36.17% | ― | ― | -45.74% | |
48 Neutral | AU$323.50M | -11.70 | -89.98% | ― | 503.29% | 11.46% | |
43 Neutral | AU$24.73M | -6.20 | -112.59% | ― | ― | -67.74% | |
41 Neutral | AU$104.72M | -26.08 | 429.85% | ― | 44.80% | 7.69% |
Archer Materials Corporate Events
Archer Materials has advanced its quantum machine learning research program, selecting and preprocessing a publicly available dataset of more than 280,000 bank transactions to build a quantum model for financial fraud detection. By adapting the data to current quantum hardware constraints and enabling comparison with classical machine learning benchmarks, the company is positioning its quantum algorithms to address real-world financial security challenges.
With dataset preparation completed, Archer is now moving into simulations and benchmarking, expecting initial performance indications by mid-year and targeting a full quantum machine learning prototype by year-end. The project is a key element of Archer’s strategy to develop practical quantum computing applications and broaden commercialisation pathways for its quantum technology suite, potentially strengthening its role in emerging quantum-enabled financial analytics.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.33 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has released a presentation for its first-half FY26 update, to be delivered via a webinar led by Chief Executive Officer Simon Ruffell. The session, scheduled for today and including a Q&A component, signals ongoing engagement with investors and stakeholders as the company reports on its progress.
The update underscores Archer’s focus on advancing its semiconductor-based quantum technologies, including quantum computing and diagnostic applications. By maintaining open communication with the market through such briefings, Archer aims to reinforce its positioning in the emerging quantum technology space and highlight the development trajectory of its chip-based solutions.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials reported 1H FY26 progress marked by a major technical breakthrough in its carbon-based quantum computing program, achieving on-chip electrical readout of quantum states via EDMR and SET devices and validating CMOS-compatible, wafer-scale manufacturing. The company advanced its 12CQ project with cryogenic TMR sensor performance, strengthened partnerships with Emergence Quantum and CSIRO, and remains on track for targeted qubit demonstration in 2026.
In medical diagnostics, Archer enhanced its Biochip strategy through a dual graphene and silicon platform, completing an initial silicon-based blood potassium sensor project with IMEC and demonstrating clinically aligned accuracy in human blood tests. The company is targeting a functional Biochip prototype in 2026 for point-of-care chronic kidney disease testing, supported by a strong cash position of $10.3 million and an expanded board to accelerate R&D and commercialisation.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has released the presentation that its CEO Simon Ruffell will deliver during an investor webinar scheduled for 11:00am AEDT on 29 January 2026, which will be followed by a Q&A session. The event underlines the company’s ongoing investor engagement and provides a platform to update shareholders on its Q2 FY26 progress and strategic developments in quantum and semiconductor technologies.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
In the December quarter of FY26, Archer Materials reported significant technical and strategic progress across its core quantum and biochip programs, including improved quantum state readout for its carbon-based qubit materials, successful synthesis of this material on a one‑inch silicon wafer, and demonstration of room-temperature spin lifetimes that compare favourably with leading quantum platforms. The company broadened its ecosystem by signing a collaboration with Emergence Quantum to explore graphene and carbon-based technologies for next-generation quantum and electronic devices, entered an agreement with CSIRO to develop quantum machine learning models for enhanced financial fraud detection, and, in its Biochip program, achieved clinical-standard accuracy for silicon-based blood potassium testing devices in collaboration with IMEC, a shift that could lower costs, de-risk supply chains and accelerate regulatory and commercial pathways; Archer ended the quarter with $10.3 million in cash (excluding a subsequent $2.1 million R&D tax rebate) and strengthened its board with the appointment of experienced health industry executive Andrew Just as a non-executive director.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has announced it will host an investor webinar to deliver its quarterly update for the period ended 31 December 2025, with CEO Simon Ruffell presenting and taking questions from participants. The event underscores the company’s ongoing engagement with investors as it advances its portfolio of quantum and semiconductor technologies, providing stakeholders with an opportunity to gain insights into recent developments and the company’s strategic progress.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has reported significant technical progress across its quantum computing, quantum sensing and Biochip programs in 2025 and laid out a commercial roadmap for 2026. The company advanced its carbon-based quantum technology by demonstrating electrical gating in single electron transistor devices, improving electron spin lifetimes to 800 nanoseconds, and achieving qubit control through new resonator circuits, collectively de-risking the path toward a functional qubit demonstration targeted for early 2026 and positioning the platform for scalable manufacturing. Archer also expanded its quantum sensing and quantum machine learning initiatives, including a fraud-detection project for financial transactions that could be adapted to broader applications. In parallel, its Biochip program for blood potassium monitoring reached precision levels aligned with clinical lab standards and progressed toward manufacturable silicon- and graphene-based prototypes with partners such as IMEC, supporting future external trials and potential expansion into additional biomarkers. Management frames 2026 as an inflection year in which all core programs are expected to move from research-led development toward product demonstrations and commercial partnerships, signalling a shift toward real-world deployments and active commercial engagement.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.